Increased Atherosclerosis in HIV-Infected Humanized Mice Is Caused by a Single Viral Protein, Nef

Antiretroviral therapy suppresses human immunodeficiency virus (HIV) replication, reverses immunodeficiency, and reduces AIDS-related symptoms, but non-AIDS comorbidities like cardiovascular diseases remain a major challenge for people with HIV (PWH). The pathogenic mechanisms driving these comorbidities are poorly understood. We previously showed that the HIV protein Nef contributes to chronic inflammation in PWH. Here, we explored Nef's role in HIV-associated atherosclerosis using a novel model: HIV-infected humanized mice expressing a gain-of-function mutant of proprotein convertase subtilisin/kexin type 9 (PCSK9) and fed a high-fat diet. Comparing atherosclerosis in uninfected mice to those infected with Nef-positive or Nef-deficient HIV-1, we found that Nef exacerbates atherosclerotic changes by increasing inflammation. These results identify Nef as a key driver of HIV-related atherosclerosis and provide a platform for testing therapeutic interventions targeting Nef to mitigate cardiovascular risks in PWH.

Authors

Institutions

Publication Details

Journal
The Journal of Infectious Diseases
Published
2025-04-09
DOI
https://doi.org/10.1093/infdis/jiaf192
Citations
3
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
6.76

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increased Atherosclerosis in HIV-Infected Humanized Mice Is Caused by a Single Viral Protein, Nef

Larisa Dubrovsky, Olga Rodriguez, Yi‐Chien Lee, Chris Albanese et al.
3 citations
The Journal of Infectious Diseases
HIV-related health complications and treatments
6.76
article

Increased Atherosclerosis in HIV-Infected Humanized Mice Is Caused by a Single Viral Protein, Nef

Larisa Dubrovsky, Olga Rodriguez, Yi‐Chien Lee, Chris Albanese, Beda Břicháček, Anastas Popratiloff, Marta Catálfamo, Kyle Korolowicz, Michael Bukrinsky, Yongsen Wang, Dmitri Sviridov, Tatiana Pushkarsky
article en
3 citations

Abstract

Antiretroviral therapy suppresses human immunodeficiency virus (HIV) replication, reverses immunodeficiency, and reduces AIDS-related symptoms, but non-AIDS comorbidities like cardiovascular diseases remain a major challenge for people with HIV (PWH). The pathogenic mechanisms driving these comorbidities are poorly understood. We previously showed that the HIV protein Nef contributes to chronic inflammation in PWH. Here, we explored Nef's role in HIV-associated atherosclerosis using a novel model: HIV-infected humanized mice expressing a gain-of-function mutant of proprotein convertase subtilisin/kexin type 9 (PCSK9) and fed a high-fat diet. Comparing atherosclerosis in uninfected mice to those infected with Nef-positive or Nef-deficient HIV-1, we found that Nef exacerbates atherosclerotic changes by increasing inflammation. These results identify Nef as a key driver of HIV-related atherosclerosis and provide a platform for testing therapeutic interventions targeting Nef to mitigate cardiovascular risks in PWH.

The Journal of Infectious DiseasesVol. 232(1)
Baker Heart and Diabetes Institute (AU), Georgetown University (US), George Washington University (US), Georgetown University Medical Center (US), Imaging Center (US), Monash University (AU)
National Institutes of Health, University of North Carolina at Chapel Hill, University of California, San Diego, National Heart, Lung, and Blood Institute
Good health and well-being
Openalex Percentile: Top 4%
HIV-related health complications and treatments
6.76
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.